Literature DB >> 9005869

Reversible Schwann cell hyperplasia and sprouting of sensory and sympathetic neurites after intraventricular administration of nerve growth factor.

J Winkler1, G A Ramirez, H G Kuhn, D A Peterson, P A Day-Lollini, G R Stewart, M H Tuszynski, F H Gage, L J Thal.   

Abstract

Substantial dysfunction and loss of cholinergic neurons occur in Alzheimer's disease (AD). Nerve growth factor (NGF) is a potent neurotrophic factor for cholinergic basal forebrain neurons, and the use of NGF to stimulate residual dysfunctional cells in AD is being considered. To define the effects of NGF on other cell populations in the brain, NGF was continuously infused into the lateral ventricle of rats for 7 weeks. At the end of treatment, Schwann cell hyperplasia and abundant sensory and sympathetic neurite sprouting were observed in the subpial region of the medulla oblongata and the spinal cord. Following withdrawal of NGF, the Schwann cell hyperplasia and sprouting of sensory and sympathetic neurites disappeared completely. These findings suggest that better temporal and spatial delivery systems for NGF must be explored to limit potential undesirable side effects while maintaining the survival and function of diseased basal forebrain cholinergic neurons.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9005869     DOI: 10.1002/ana.410410114

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  32 in total

1.  Nerve growth factor (NGF) augments cortical and hippocampal cholinergic functioning after p75NGF receptor-mediated deafferentation but impairs inhibitory avoidance and induces fear-related behaviors.

Authors:  J Winkler; G A Ramirez; L J Thal; J J Waite
Journal:  J Neurosci       Date:  2000-01-15       Impact factor: 6.167

Review 2.  Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.

Authors:  Elliott J Mufson; Scott E Counts; Sylvia E Perez; Stephen D Ginsberg
Journal:  Expert Rev Neurother       Date:  2008-11       Impact factor: 4.618

Review 3.  Potential therapeutic uses of BDNF in neurological and psychiatric disorders.

Authors:  Alan H Nagahara; Mark H Tuszynski
Journal:  Nat Rev Drug Discov       Date:  2011-03       Impact factor: 84.694

Review 4.  Localized delivery of proteins in the brain: can transport be customized?

Authors:  M F Haller; W M Saltzman
Journal:  Pharm Res       Date:  1998-03       Impact factor: 4.200

5.  Nerve Growth Factor Protects Against Pyrethroid-Induced Endoplasmic Reticulum (ER) Stress in Primary Hippocampal Neurons.

Authors:  Muhammad M Hossain; Jason R Richardson
Journal:  Toxicol Sci       Date:  2020-03-01       Impact factor: 4.849

6.  Swedish Nerve Growth Factor Mutation (NGFR100W) Defines a Role for TrkA and p75NTR in Nociception.

Authors:  Kijung Sung; Luiz F Ferrari; Wanlin Yang; ChiHye Chung; Xiaobei Zhao; Yingli Gu; Suzhen Lin; Kai Zhang; Bianxiao Cui; Matthew L Pearn; Michael T Maloney; William C Mobley; Jon D Levine; Chengbiao Wu
Journal:  J Neurosci       Date:  2018-02-26       Impact factor: 6.167

7.  Angiotensin AT2-receptor stimulation improves survival and neurological outcome after experimental stroke in mice.

Authors:  Katja Schwengel; Pawel Namsolleck; Kristin Lucht; Bettina H Clausen; Kate L Lambertsen; Veronica Valero-Esquitino; Christa Thöne-Reineke; Susanne Müller; Robert E Widdop; Kate M Denton; Masatsugu Horiuchi; Masaru Iwai; Francesco Boato; Björn Dahlöf; Anders Hallberg; Thomas Unger; U Muscha Steckelings
Journal:  J Mol Med (Berl)       Date:  2016-03-16       Impact factor: 4.599

Review 8.  Mesenchymal Stromal Cell Therapies for Neurodegenerative Diseases.

Authors:  Nathan P Staff; David T Jones; Wolfgang Singer
Journal:  Mayo Clin Proc       Date:  2019-05       Impact factor: 7.616

9.  Behavioral effects of neurotrophic factor supplementation in aging.

Authors:  G M Rose
Journal:  Age (Omaha)       Date:  1999-01

10.  Nerve Growth Factor Gene Therapy: Activation of Neuronal Responses in Alzheimer Disease.

Authors:  Mark H Tuszynski; Jennifer H Yang; David Barba; Hoi-Sang U; Roy A E Bakay; Mary M Pay; Eliezer Masliah; James M Conner; Peter Kobalka; Subhojit Roy; Alan H Nagahara
Journal:  JAMA Neurol       Date:  2015-10       Impact factor: 18.302

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.